Prescient Therapeutics Ltd (ASX:PTX)'s Steven Yatomi-Clarke outlines the company's oncology treatment vision in a new interview with Proactive. The healthcare stock adopts a portfolio approach when it comes to developing its clinical pipeline, and it's just announced a new clinic-ready CAR-T enhancement platform. Essentially, Prescient's CellPryme-M platform has been proven to produce a superior cell product for CAR-T therapy, and it's ready to use in clinical trials. Yatomi-Clarke said CellPryme is Prescient’s second cell therapy platform and is a valuable addition to the company’s pipeline.
Prescient Therapeutics delivers new clinic-ready cell therapy technology
